Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Gamelin

Showing results (61-70 of 75) with videos related to

Pageof 8
Sort By:
British Journal of Cancer|September 18, 2008
Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patientsE Rouits, V Charasson, A Pétain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 16, 2001
Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patientsY Bécouarn, E Gamelin, B Coudert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2002
Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patientsL Zelek, P Cottu, M Tubiana-Hulin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2002
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patientsC Louvet, T André, J M Tigaud, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 13, 2000
Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate-use programS Brienza, M A Bensmaïne, P Soulié, et al.
Seminars in Oncology|March 29, 2001
Randomized adjuvant study comparing two schemes of 5-fluorouracil and leucovorin in stage B2 and C colon adenocarcinoma: study design and preliminary safety results. Groupe d'Etude et de Recherche Clinique en Oncologie RadiotherapiesT André, P Colin, C Louvet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 15, 2002
Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patientsJ-F Seitz, J Bennouna, B Paillot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 5, 2002
Multicenter phase II-III study of oxaliplatin plus cyclophosphamide vs. cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patientsJ L Misset, P Vennin, P H Chollet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 31, 2009
A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802)M Ychou, J-L Raoul, J-Y Douillard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1996
Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidinesD Machover, E Diaz-Rubio, A de Gramont, et al.
Pageof 8

Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
British Journal of Cancer|September 18, 2008
Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patientsE Rouits, V Charasson, A Pétain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 16, 2001
Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patientsY Bécouarn, E Gamelin, B Coudert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2002
Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patientsL Zelek, P Cottu, M Tubiana-Hulin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2002
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patientsC Louvet, T André, J M Tigaud, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 13, 2000
Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate-use programS Brienza, M A Bensmaïne, P Soulié, et al.
Seminars in Oncology|March 29, 2001
Randomized adjuvant study comparing two schemes of 5-fluorouracil and leucovorin in stage B2 and C colon adenocarcinoma: study design and preliminary safety results. Groupe d'Etude et de Recherche Clinique en Oncologie RadiotherapiesT André, P Colin, C Louvet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 15, 2002
Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patientsJ-F Seitz, J Bennouna, B Paillot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 5, 2002
Multicenter phase II-III study of oxaliplatin plus cyclophosphamide vs. cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patientsJ L Misset, P Vennin, P H Chollet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 31, 2009
A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802)M Ychou, J-L Raoul, J-Y Douillard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1996
Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidinesD Machover, E Diaz-Rubio, A de Gramont, et al.
Pageof 8